VistaGen Therapeutics, Inc. (VTGN): Price and Financial Metrics

VistaGen Therapeutics, Inc. (VTGN): $4.83

0.09 (-1.83%)

POWR Rating

Component Grades








Add VTGN to Watchlist
Sign Up

Industry: Biotech




#147 of 356

in industry

VTGN Price/Volume Stats

Current price $4.83 52-week high $24.71
Prev. close $4.92 52-week low $1.62
Day low $4.83 Volume 884
Day high $4.83 Avg. volume 282,108
50-day MA $5.03 Dividend yield N/A
200-day MA $4.10 Market Cap 130.53M

VTGN Stock Price Chart Interactive Chart >


  • Growth is the dimension where VTGN ranks best; there it ranks ahead of 82.9% of US stocks.
  • VTGN's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • VTGN ranks lowest in Stability; there it ranks in the 0th percentile.

VTGN Stock Summary

  • With a price/sales ratio of 163.37, VISTAGEN THERAPEUTICS INC has a higher such ratio than 98.16% of stocks in our set.
  • As for revenue growth, note that VTGN's revenue has grown -536.69% over the past 12 months; that beats the revenue growth of merely 0.15% of US companies in our set.
  • The volatility of VISTAGEN THERAPEUTICS INC's share price is greater than that of 96.6% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VISTAGEN THERAPEUTICS INC are BCDA, INO, GSIT, DRRX, and CRIS.
  • Visit VTGN's SEC page to see the company's official filings. To visit the company's web site, go to

VTGN Valuation Summary

  • In comparison to the median Healthcare stock, VTGN's price/earnings ratio is 113.38% lower, now standing at -3.9.
  • Over the past 93 months, VTGN's price/earnings ratio has gone down 3.7.

Below are key valuation metrics over time for VTGN.

Stock Date P/S P/B P/E EV/EBIT
VTGN 2023-12-29 171.5 3.9 -3.9 -2.9
VTGN 2023-12-28 174.8 4.0 -4.0 -3.0
VTGN 2023-12-27 171.5 3.9 -3.9 -2.9
VTGN 2023-12-26 177.5 4.0 -4.1 -3.1
VTGN 2023-12-22 176.5 4.0 -4.0 -3.0
VTGN 2023-12-21 170.1 3.9 -3.9 -2.9

VTGN Growth Metrics

    Its 4 year cash and equivalents growth rate is now at -53.61%.
  • Its 3 year price growth rate is now at 46.48%.
  • Its 5 year cash and equivalents growth rate is now at -53.61%.
VTGN's revenue has moved down $1,831,500 over the prior 15 months.

The table below shows VTGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 -0.3639 -57.8309 -63.7091
2022-09-30 -0.1856 -59.9431 -64.6911
2022-06-30 1.0649 -55.0519 -60.3775
2022-03-31 1.1089 -45.2565 -48.7075
2021-12-31 1.5119 -34.9499 -61.579
2021-09-30 1.4676 -27.893 -56.4881

VTGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTGN has a Quality Grade of C, ranking ahead of 36.05% of graded US stocks.
  • VTGN's asset turnover comes in at 0.017 -- ranking 376th of 682 Pharmaceutical Products stocks.
  • SAGE, SVRA, and EDIT are the stocks whose asset turnover ratios are most correlated with VTGN.

The table below shows VTGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 1 -4.522
2021-03-31 0.018 1 -3.130
2020-12-31 0.018 1 -2.501
2020-09-30 0.036 1 -2.651
2020-06-30 0.000 NA -3.134
2020-03-31 0.000 NA -3.789

VTGN Price Target

For more insight on analysts targets of VTGN, see our VTGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.12 (Strong Buy)

VistaGen Therapeutics, Inc. (VTGN) Company Bio

VistaGen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops products for patients with diseases and disorders involving the central nervous system. VistaGen Therapeutics serves customers in the United States.

VTGN Latest News Stream

Event/Time News Detail
Loading, please wait...

VTGN Latest Social Stream

Loading social stream, please wait...

View Full VTGN Social Stream

Latest VTGN News From Around the Web

Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

SOUTH SAN FRANCISCO, Calif., December 27, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain. AV-101 is the Company’s investigational oral prodrug of 7-chloro-ky

Yahoo | December 27, 2023

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […]

Yahoo | December 20, 2023

Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week

Key Insights Significant control over Vistagen Therapeutics by retail investors implies that the general public has...

Yahoo | November 29, 2023

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call. [Operator Instructions] Please note this call is being recorded. I will be standing by if you should need any assistance. It is now my pleasure […]

Yahoo | November 11, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., November 09, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.

Yahoo | November 9, 2023

Read More 'VTGN' Stories Here

VTGN Price Returns

1-mo 0.52%
3-mo 34.54%
6-mo -10.97%
1-year -13.90%
3-year -93.53%
5-year -88.33%
YTD -6.03%
2023 66.34%
2022 -94.72%
2021 0.52%
2020 181.28%
2019 -54.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!